Asia Pacific Vaccine Market Growth, Trends & Forecast 2034

What is Driving the Growth of the Asia Pacific Vaccine Market?

The Asia Pacific vaccine market is witnessing remarkable growth due to rising incidence of infectious diseases, increasing awareness of immunization, and technological advancements in vaccine development. Valued at USD 4.56 Billion in 2024, the market is projected to reach USD 9.66 Billion by 2034, expanding at a CAGR of 7.80% during the forecast period.

Vaccines are essential in preventing infectious diseases, improving public health, and reducing the burden on healthcare systems. The Asia Pacific region has emerged as a key market due to government-backed immunization programs, rising healthcare expenditure, and increasing availability of advanced vaccines.

Asia Pacific Vaccine Market Overview

Several factors are fueling the growth of the vaccine market in Asia Pacific:

• Increasing prevalence of infectious diseases such as influenza, hepatitis, and pneumococcal disease.

• Rising investment in vaccine R&D and introduction of innovative platforms, including recombinant and conjugate vaccines.

• Government-led immunization programs supporting widespread vaccination coverage.

• Rising healthcare awareness among adults, pediatrics, and geriatric populations.

• Collaborations between global and regional vaccine manufacturers to enhance production capacity.

The combination of innovative vaccines, strong regulatory support, and a growing immunization agenda is enabling rapid market expansion.

Market Segmentation by Composition

The Asia Pacific vaccine market can be segmented based on composition:

• Combination Vaccine:

  • Includes vaccines targeting multiple pathogens in a single dose.

  • Reduces the number of injections, improving compliance and immunization coverage.

• Mono Vaccine:

  • Vaccines targeting a single disease, ideal for specific outbreaks or targeted immunization programs.

  • Frequently used in routine pediatric and adult vaccination schedules.

Combination vaccines are expected to see strong adoption due to efficiency in mass immunization campaigns.

Market Segmentation by Type

Vaccine types in the Asia Pacific region include:

• Recombinant and Conjugate Vaccines:

  • Use genetically engineered proteins or polysaccharide conjugates.

  • Effective for hepatitis B, HPV, and pneumococcal diseases.

• Inactivated Vaccines:

  • Contain killed pathogens that cannot cause disease.

  • Commonly used for influenza, polio, and rabies vaccines.

• Live Attenuated Vaccines:

  • Contain weakened forms of the virus.

  • Used for measles, mumps, rubella, and varicella vaccines.

• Toxoid Vaccines:

  • Contain inactivated bacterial toxins, effective against diseases like tetanus and diphtheria.

• Others:

  • Includes novel vaccines, such as mRNA-based vaccines for COVID-19 and emerging infectious diseases.

Recombinant and conjugate vaccines are gaining momentum due to their enhanced efficacy and broader protection.

Market Segmentation by Age Group

Vaccine adoption varies across age groups:

• Pediatric:

  • Children are prioritized for routine immunization programs.

  • Vaccines include DPT, polio, measles, and hepatitis B.

• Adult:

  • Adult vaccination programs focus on influenza, HPV, and hepatitis vaccines.

  • Increasing awareness drives adoption in working-age populations.

• Geriatric:

  • Elderly populations receive vaccines to prevent influenza, pneumococcal disease, and shingles.

  • Growing geriatric population across Asia Pacific drives market demand.

Pediatric vaccines dominate the market due to government-supported immunization schedules, while adult and geriatric vaccines show rising growth potential.

Market Segmentation by Indication

The Asia Pacific vaccine market addresses multiple disease indications:

• Pneumococcal Disease

• Influenza

• Typhoid

• Rabies

• Yellow Fever

• Human Papilloma Virus (HPV)

• Meningococcal Disease

• Varicella, Measles, Mumps, and Rubella (MMRV)

• Diphtheria, Pertussis, and Tetanus (DPT)

• Polio

• Hepatitis (A, B, C)

• Japanese Encephalitis (JE)

• Others

Influenza and pneumococcal vaccines are among the most widely administered in adults and geriatrics, whereas pediatric programs focus on DPT, polio, and MMRV vaccines.

Market Segmentation by Route of Administration

Vaccines in the Asia Pacific are administered via different routes:

• Injectable:

  • Most common route for pediatric, adult, and geriatric vaccines.

  • Provides high efficacy and rapid immune response.

• Oral:

  • Used for polio and rotavirus vaccines.

  • Enhances patient compliance and ease of administration.

• Nasal:

  • Primarily used for influenza vaccines.

  • Offers non-invasive immunization, suitable for mass campaigns.

Injectable vaccines dominate the market, but oral and nasal vaccines are expected to grow due to convenience and non-invasive administration.

Market Segmentation by Region

The Asia Pacific vaccine market is geographically segmented as follows:

• China:

  • Largest market due to high population, increasing government immunization programs, and local vaccine manufacturing.

  • Rapid adoption of innovative vaccines like HPV and pneumococcal vaccines.

• Japan:

  • Advanced healthcare infrastructure and strong focus on adult and geriatric immunization.

  • Investments in recombinant and novel vaccines drive market growth.

• India:

  • Expanding public immunization programs and affordable vaccine production.

  • Strong presence of companies like Serum Institute of India and Bharat Biotech.

• ASEAN Countries:

  • Includes Singapore, Malaysia, Thailand, and Indonesia.

  • Growing healthcare expenditure and government-supported vaccination campaigns.

• Australia:

  • High adoption of vaccines in pediatric, adult, and geriatric populations.

  • Focus on seasonal influenza and HPV vaccination.

• Others:

  • Emerging markets in South Korea, Vietnam, and the Philippines are witnessing increasing vaccine awareness and adoption.

China, Japan, and India are the major contributors, while ASEAN countries and Australia show high growth potential.

Key Companies in the Asia Pacific Vaccine Market

Leading companies in the Asia Pacific vaccine market include:

• CSL: Innovates in recombinant vaccines and plasma-derived products.

• Bharat Biotech International Limited: Focuses on pediatric and adult vaccines, including rotavirus, JE, and COVID-19 vaccines.

• GSK plc: Offers pediatric, adult, and seasonal influenza vaccines.

• Pfizer Inc.: Develops recombinant and novel vaccines for multiple indications.

• AstraZeneca PLC: Focuses on influenza and emerging infectious disease vaccines.

• Biological E. Limited: Produces affordable vaccines for pediatric and adult populations.

• Serum Institute of India: World’s largest vaccine manufacturer by volume, covering DPT, polio, MMR, and influenza vaccines.

• Takeda: Specializes in innovative recombinant and conjugate vaccines.

• Merck & Co., Inc.: Provides a broad portfolio of vaccines for HPV, hepatitis, and pediatric diseases.

• Sanofi: Develops seasonal influenza, pediatric, and adult vaccines.

• Abbott: Focuses on vaccine R&D collaborations and clinical programs.

Competition in the market is driven by innovation, regional presence, strategic partnerships, and government collaborations.

Key Market Drivers

• Increasing prevalence of infectious diseases in Asia Pacific.

• Government-backed immunization programs driving pediatric and adult vaccination.

• Technological innovations in vaccines, including recombinant, conjugate, and mRNA vaccines.

• Expansion of healthcare infrastructure and immunization coverage.

• Growing awareness of adult and geriatric vaccination programs.

These factors collectively contribute to the rapid expansion of the Asia Pacific vaccine market.

Future Trends

• mRNA and DNA-based vaccines: Adoption for emerging infectious diseases.

• Combination vaccines: Reducing the number of injections, increasing compliance.

• Digital immunization tracking systems: Improving vaccination rates and monitoring.

• Expansion in emerging markets: Focus on India, ASEAN countries, and Australia.

• Public-private collaborations: Enhancing vaccine accessibility and production capacity.

Integration of advanced technologies, innovative vaccine platforms, and strategic collaborations will support sustainable market growth.

Discover More Reports

Antimicrobial Hospital Curtains Market

Mastopexy Market

Gas Chromatography Market

Guidewires Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com